In the past week, ONCY stock has gone up by 5.98%, with a monthly gain of 9.73% and a quarterly surge of 21.57%. The volatility ratio for the week is 4.94%, and the volatility levels for the last 30 days are 5.27% for Oncolytics Biotech, Inc. The simple moving average for the last 20 days is 12.22% for ONCY stock, with a simple moving average of -19.06% for the last 200 days.
Is It Worth Investing in Oncolytics Biotech, Inc. (NASDAQ: ONCY) Right Now?
Additionally, the 36-month beta value for ONCY is 1.90. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ONCY is 70.65M and currently, short sellers hold a 1.31% ratio of that float. The average trading volume of ONCY on May 10, 2024 was 310.30K shares.
ONCY) stock’s latest price update
The stock of Oncolytics Biotech, Inc. (NASDAQ: ONCY) has increased by 5.08 when compared to last closing price of 1.18. Despite this, the company has experienced a 5.98% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-05-09 that Oncolytics Biotech, Inc. (NASDAQ:ONCY ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jon Patton – Director, Investor Relations and Communication Matthew Coffey – President, CEO & Director Thomas Heineman – Chief Medical Officer, Oncolytics Biotech (U.S.) Kirk Look – CFO Conference Call Participants John Newman – Canaccord Genuity Operator Good afternoon and welcome to Oncolytics Biotech’s First Quarter 2024 Conference Call. [Operator Instructions].
Analysts’ Opinion of ONCY
Many brokerage firms have already submitted their reports for ONCY stocks, with Maxim Group repeating the rating for ONCY by listing it as a “Buy.” The predicted price for ONCY in the upcoming period, according to Maxim Group is $3 based on the research report published on October 06, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ONCY reach a price target of $15. The rating they have provided for ONCY stocks is “Buy” according to the report published on February 17th, 2021.
ONCY Trading at 15.14% from the 50-Day Moving Average
After a stumble in the market that brought ONCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.47% of loss for the given period.
Volatility was left at 5.27%, however, over the last 30 days, the volatility rate increased by 4.94%, as shares surge +7.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.57% upper at present.
During the last 5 trading sessions, ONCY rose by +5.98%, which changed the moving average for the period of 200-days by -57.24% in comparison to the 20-day moving average, which settled at $1.1095. In addition, Oncolytics Biotech, Inc. saw -8.15% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ONCY
The total capital return value is set at -0.98. Equity return is now at value -101.82, with -72.28 for asset returns.
Based on Oncolytics Biotech, Inc. (ONCY), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -67.25. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 113.77.
Currently, EBITDA for the company is -33.39 million with net debt to EBITDA at 0.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.01.
Conclusion
In conclusion, Oncolytics Biotech, Inc. (ONCY) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
